IL17A and hidradenitis suppurativa: A study by Navrazhina et al. reported that, in patients with hidradenitis suppurativa, higher baseline serum IL-17A levels were associated with greater reductions in inflammatory cytokines in perilesional skin after 12 weeks of brodalumab treatment [22].